Lipids

BJC Learning - Lipids

Welcome to this lipids modular e-learning programme looking at dyslipidaemia in clinical practice.

It is now widely established from large outcome studies that lowering cholesterol leads to the prevention of cardiovascular disease and mortality. This has led to HMG CoA reductase inhibitors (statins) becoming the cornerstone of dyslipidaemia treatment along with lifestyle changes. More recently, newer classes of lipid-lowering treatment have become available leading to more options for clinicians to further treat high cholesterol.

In this modular programme we will first be introduced in module 1 to lipid metabolism and its role in atherosclerosis. Module 2 will discuss how to assess cardiovascular risk and why management of dyslipidaemia is important. Module 3 will review the clinical diagnosis of dyslipidaemia. Module 4 will look at the role of individual drugs and lifestyle interventions. Modules will be complemented by case studies.

Each module will have a series of multiple-choice questions for self-assessment. Its five hours of learning across four modules leads to 5 CPD credits.

Novartis has provided sponsorship to support the latest revision of this e-learning programme. The content has been independently written by leading UK experts. Novartis had no input into the writing of the modules and had no editorial control over the content.

Original modular programme
Dr Dermot Neely, Specialist Adviser on Lipids, Academic Health Science Network, North East and North Cumbria
Dr Mike Khan, Chief Medical Officer, Silence Therapeutics plc
Dr David Thompson, Clinical Research Fellow, International Centre for Circulatory Health, Imperial College London, London
Modules revised in 2021 by:
Programme editor: Dr Dermot Neely
Dr Mariana Abdel Malek, SpR, Imperial College Healthcare NHS Trust
Dr Jaimini Cegla, Consultant in Chemical Pathology and Metabolic Medicine, Imperial College Healthcare NHS Trust
Dr Gavin Mercer-Smith, SpR, Newcastle upon Tyne Hospitals NHS Foundation Trust
Professor Tim Reynolds, Consultant Chemical Pathologist, University Hospitals of Derby and Burton

Lipids module 1: lipid metabolism and its role in atherosclerosis

Released 17 March 2021   Programme: Lipids 1 CPD/CME credit

Lipids module 1: lipid metabolism and its role in atherosclerosis
  • Understand the essential lipid fractions that form the building blocks of lipid physiology
  • Review the mechanisms which facilitate lipid transport between tissues
  • Describe the role of lipid particles in atherogenesis
  • Understand clinically important cholesterol measurements

Lipids module 2: cardiovascular risk

Released 17 March 2021   Programme: Lipids 1 CPD/CME credit

Lipids module 2: cardiovascular risk
  • Define the concept of ‘risk factors’
  • Understand the need for risk assessment and screening
  • Utilise ‘risk engines’ and scoring systems
  • Assess which patients to exclude from standard risk assessment

Lipids module 3: clinical diagnosis of dyslipidaemia

Released 17 March 2021   Programme: Lipids 1 CPD/CME credit

Lipids module 3: clinical diagnosis of dyslipidaemia
  • Review the clinical diagnosis of dyslipidaemia
  • Use clinical findings and abnormalities of the lipid profile to identify and diagnose patients with dyslipidaemia
  • Understand components of the lipid profile and how they are measured and calculated
  • Recognise the role of lipid profiling in coronary risk assessment including measurement of lipoprotein(a)

Lipids module 4: treatment of dyslipidaemia

Released 17 March 2021   Programme: Lipids 2 CPD/CME credits

Lipids module 4: treatment of dyslipidaemia
  • Assess evidence for lipid lowering
  • Review which patients are eligible for lipid management
  • Utilise lifestyle (diet and exercise) interventions
  • Define drug classes for the modification of lipids